HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution.

Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for strategies to rapidly develop neutralizing monoclonal antibodies that can function as prophylactic and therapeutic agents and to help guide vaccine design. Here, we demonstrate that engineering approaches can be used to refocus an existing antibody that neutralizes one virus but not a related virus. Through a rapid affinity maturation strategy, we engineered CR3022, a SARS-CoV-1-neutralizing antibody, to bind to the receptor binding domain of SARS-CoV-2 with >1000-fold increased affinity. The engineered CR3022 neutralized SARS-CoV-2 and provided prophylactic protection from viral challenge in a small animal model of SARS-CoV-2 infection. Deep sequencing throughout the engineering process paired with crystallographic analysis of engineered CR3022 elucidated the molecular mechanisms by which the antibody can accommodate sequence differences in the epitopes between SARS-CoV-1 and SARS-CoV-2. This workflow provides a blueprint for the rapid broadening of neutralization of an antibody from one virus to closely related but resistant viruses.
AuthorsFangzhu Zhao, Meng Yuan, Celina Keating, Namir Shaabani, Oliver Limbo, Collin Joyce, Jordan Woehl, Shawn Barman, Alison Burns, Quoc Tran, Xueyong Zhu, Michael Ricciardi, Linghang Peng, Jessica Smith, Deli Huang, Bryan Briney, Devin Sok, David Nemazee, John R Teijaro, Ian A Wilson, Dennis R Burton, Joseph G Jardine
JournalScience signaling (Sci Signal) Vol. 16 Issue 798 Pg. eabk3516 (08 15 2023) ISSN: 1937-9145 [Electronic] United States
PMID37582161 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antibodies, Viral
  • Antibodies, Neutralizing
Topics
  • Animals
  • SARS-CoV-2 (genetics)
  • COVID-19 (prevention & control)
  • Antibodies, Viral
  • Neutralization Tests
  • Antibodies, Neutralizing

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: